Placebo + ISIS 703802 40 mg + ISIS 703802 80 mg + ISIS 703802 20 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
NAFLD
Conditions
NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Trial Timeline
Dec 21, 2017 → Feb 24, 2020
NCT ID
NCT03371355About Placebo + ISIS 703802 40 mg + ISIS 703802 80 mg + ISIS 703802 20 mg
Placebo + ISIS 703802 40 mg + ISIS 703802 80 mg + ISIS 703802 20 mg is a phase 2 stage product being developed by Ionis Pharmaceuticals for NAFLD. The current trial status is completed. This product is registered under clinical trial identifier NCT03371355. Target conditions include NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03371355 | Phase 2 | Completed |
Competing Products
15 competing products in NAFLD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lanifibranor | Inventiva | Phase 2 | 47 |
| Saroglitazar | Zydus Lifesciences | Approved | 85 |
| AZD4076 + Placebo | AstraZeneca | Phase 1 | 33 |
| AZ compound | AstraZeneca | Phase 2 | 52 |
| Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo | AstraZeneca | Phase 2 | 52 |
| LCQ908 + placebo | Novartis | Phase 2 | 52 |
| Placebo + RO5093151 | Roche | Phase 1 | 33 |
| Semaglutide Pen Injector + Placebo | Novo Nordisk | Phase 2 | 51 |
| Ketohexokinase inhibition | Pfizer | Phase 2 | 51 |
| PF-05221304 Monotherapy + PF-06865571 Monotherapy + Placebo + PF-05221304 and PF-06865571 Combination | Pfizer | Phase 2 | 51 |
| BMS-986036 | Bristol Myers Squibb | Phase 1 | 32 |
| ALN-PNP + Placebo | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Legalon® 140 mg | Viatris | Pre-clinical | 20 |
| Elobixibat + Placebo oral tablet | Ipsen | Phase 2 | 49 |
| EDP 305 + Placebo | Enanta Pharmaceuticals | Phase 1 | 25 |